In Vitro Assessments of Antimicrobial Activity (IVAAA)

The In Vitro Assessments of Antimicrobial Activity (IVAAA) Indefinite Delivery/Indefinite Quantity (IDIQ) contract is a master vehicle established by the National Institute of Allergy and Infectious Diseases (NIAID) to provide comprehensive in vitro testing and screening capabilities for antimicrobial research. The contract focuses on evaluating the effectiveness of experimental compounds against a wide range of pathogens, including viruses, bacteria, and fungi across various biosafety levels. The overarching goal is to support NIAID's research efforts in developing medical countermeasures and understanding infectious disease treatments through specialized laboratory testing services.

The task orders under this IDIQ consistently involve specific in vitro screening and assessment activities, typically ranging from $100,000 to $2.5 million with durations between 12-24 months. Frequent prime contractors include academic research institutions such as Utah State University, University of Alabama at Birmingham, University of Texas Health Science Center at San Antonio, and specialized research organizations like the American Type Culture Collection and Element Materials Technology (JMI Laboratories). Most task orders are firm fixed-price contracts with no specific small business set-aside designations, and performance locations are primarily at the contractors' facilities in states like Utah, Alabama, Texas, and Iowa. The contracts consistently support NIAID's mission of conducting and supporting research to better understand, treat, and prevent infectious, immunologic, and allergic diseases through rigorous scientific testing and evaluation.